Details of the Drug Reposition

General Information of This Drug (ID: DMLMNFX)

Drug Name
Omaveloxolone   DMLMNFX
Synonyms
RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Friedreich's ataxia DIS5DV35 8A03.10 Approved [1]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Melanoma DIS1RRCY 2C30 Phase 1/2 [2]
------------------------------------------------------------------------------------
1 Clinical trial Indication(s)
Indication Name Indication ID ICD-11 Status REF
Psychiatric disorder DISKFW6V 6E8Z Clinical trial [3]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216718.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin. Arch Dermatol Res. 2014 Jul;306(5):447-54.